Doctor Hao-Yu Wang
Fuwai Hospital, CAMS and PUMC, Beijing (China)
Membership:
ESC Professional Member
EAPCI Member
Biography
Department of Cardiology, Coronary Heart Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Contributor content
Presentation
Presentation
High-sensitivity C-Reactive protein predicts post-percutaneous coronary intervention cardiovascular risk with CKD status effect: evidence from a prospective registry study
Presentation
Implications of ESC-high tthrombotic risk features and ARC-high bleeding risk criteria on clinical outcomes in all-comer patients undergoing PCI
Presentation
New insights into optimal duration of DAPT for high-risk "TWILIGHT-like" patients with diabetes mellitus undergoing PCI: a focus on diabetes mellitus as a high-risk patient group
Presentation
Effect of risk enhancers versus technical aspects of high thrombotic risk criteria on adverse clinical events after PCI: insights from 2020 ESC NSTE-ACS Guidelines
Presentation
Optimal strategy for antiplatelet therapy after coronary drug-eluting stent implantation in high-risk "TWILIGHT-like" patients with diabetes mellitus
Presentation
Usefulness of cardiometabolic index for the estimation of diabetes risk among general population in rural China: a community-based study
Presentation
Association of a favorable cardiovascular health profile (Life's Simple 7 and Fuster-BEWAT scores) with the presence of a newly proposed 4-tiered left ventricular hypertrophy
Presentation
The efficacy and safety of prolonged dual antiplatelet therapy beyond 12 months in patients with high risk of ischemic or bleeding events after PCI
Presentation
